| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
The purpose of this study is to develop new immune cell therapy using iPS cells for malignant melanoma. We focused on macrophages for immune cell therapy because the macrophage infiltration is frequently observed in solids cancers. We have decided to use iPS cell-derived macropage which genetically modified to express type I IFNs for treatment against melanoma. We call them iPS cell-derived myeloid cell lines expressing type I IFNs (iPS-ML-IFNs).
In this study, we examined the efficacy of human iPS-ML-IFNs against human melanoma cells. The iPS-ML-IFNs exhibited significant effects in inhibiting the growth of the tumors against the disseminated human melanoma cells in SCID mice. On the other hand, treatment with iPS-ML without IFNs demonstrated no inhibitory effect on cancer cell growth.
We believe this method will provide a new therapeutic modality for metastatic melanoma.
|
